Knight Therapeutics, Inc.

Knight Therapeutics, Inc.

Knight Therapeutics, Inc.

Overview
Date Founded

2015

Headquarters

3400 de Maisonneuve West,Suite 1055,Montréal, QC H3Z 3B8

Type of Company

Public

Employees (Worldwide)

973

Industries

Pharmaceuticals

Company Description

Knight Therapeutics Inc engages in acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its products include ILUVIEN, Nerlynx, Probuphine, Movantik, and Neuragen. The company was founded by Jonathan R. Goodman on November 1, 2013 and is headquartered in Montreal, Canada.

Executives & Employees

Chief Executive Officer & Director

President, Chief Operating Officer & Director

Director, Business Development

Vice President, Business Development

Board of Directors

Chairman & President at Alpex Pharma SA

Chief Executive Officer & Director at Knight Therapeutics, Inc.

President, Chief Operating Officer & Director at Knight Therapeutics, Inc.

Director at Biotoscana Investments SA

Former President at Astellas Pharma Canada, Inc.

Partner at Davies Ward Phillips & Vineberg LLP

Director at Biotoscana Investments SA

Paths to Knight Therapeutics, Inc.
Potential Connections via
Relationship Science
You
Knight Therapeutics, Inc.
Owners & Shareholders
Details Hidden

Resolute Funds Ltd. takes a contrarian, long-term approach to growth investing. They manage a private mutual fund that is sold on a restricted basis by offering memorandum. The minimum initial purchase is $150,000 and the approved Canadian jurisdictions are Ontario, Alberta, and British Columbia. The Fund is distributed through a limited number of investment advisors and is not available at discount brokers. Resolute Funds does not offer the Performance Fund directly to the public. Resolute Funds invests primarily in the stocks of small-cap and micro-cap Canadian companies in the energy minerals, industrial services and non-energy minerals sectors.

Details Hidden

Resolute Funds Ltd. takes a contrarian, long-term approach to growth investing. They manage a private mutual fund that is sold on a restricted basis by offering memorandum. The minimum initial purchase is $150,000 and the approved Canadian jurisdictions are Ontario, Alberta, and British Columbia. The Fund is distributed through a limited number of investment advisors and is not available at discount brokers. Resolute Funds does not offer the Performance Fund directly to the public. Resolute Funds invests primarily in the stocks of small-cap and micro-cap Canadian companies in the energy minerals, industrial services and non-energy minerals sectors.

Recent Transactions
Details Hidden

Knight Therapeutics, Inc. purchases Biotoscana Investments SA

Details Hidden

Knight Therapeutics, Inc. purchases Biotoscana Investments SA

Details Hidden

Knight Therapeutics, Inc. issued CAD Common Stock - Bought Deal

Transaction Clients
Lender

Advised on CRH Medical Corp. purchases Gastroenterology Anesthesia Associates LLC

Transaction Advisors
Underwriter

Advised onKnight Therapeutics, Inc. issued CAD Common Stock

Underwriter

Advised onKnight Therapeutics, Inc. issued CAD Common Stock

Legal Advisor

Advised onKnight Therapeutics, Inc. purchases Biotoscana Investments SA

Advisors & Consultants
Legal Advisor

Partner at Davies Ward Phillips & Vineberg LLP

Legal Advisor

Partner at Davies Ward Phillips & Vineberg LLP

Legal Advisor

Partner at Davies Ward Phillips & Vineberg LLP

Key Stats and Financials As of 2020
Market Capitalization
$540M
Total Enterprise Value
$297M
Earnings Per Share
$0.25
EBITDAMargin
5.59%
Enterprise Value / Sales
1.93x
TEVNet Income
9.16x
Debt TEV
0.15x
Three Year Compounded Annual Growth Rate Of Revenue
184.83%
Enterprise Value EBITDAOperating
34.55x
Revenue
$154M
Net Profit
$32.4M
EBITDA
$8.6M
Total Debt
$43.3M
Total Equity
$683M
Investments
Details Hidden

Medison Pharma Ltd. markets and distributes medical, pharmaceutical, and diagnostics devices and products. It offers services like registration, reimbursement, nursing, distribution, and marketing. The firm is a marketing group, which represents niche healthcare products from companies such as Biogen Idec, Amgen, Shire and Ipsen. The company was founded by Meir Jakobsohn in 1996 and is headquartered in Petach Tikva, Israel.

Investors
Details Hidden

President & Treasurer at Infinity Pharmaceuticals, Inc.

Suppliers
Advaxis, Inc. Medical Support Services | Princeton, New Jersey

Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ.

Akorn, Inc. Computer Software | Lake Forest, IL

Akorn is a niche generic pharmaceutical company engaged in the development, manufacture and marketing of multi-source and branded pharmaceutical products in the areas of ophthalmology, antidotes, anti-infectives, and controlled substances for pain management and anesthesia in the United States and across the globe. Our customers include physicians, optometrists, hospitals, surgery centers, clinics, long-term care, wholesalers, group purchasing organizations, retail pharmacies, and other pharmaceutical companies. Akorn is committed to serving our customers by providing an extensive line of affordable, safe and efficacious pharmaceuticals in the following markets: Ophthalmologic Pharmaceuticals: Solutions, Ointments, Gels, and Injectables The Company’s Ophthalmic segment markets diagnostic products, including mydriatics and cycloplegics, anesthetics, topical stains, gonioscopic solutions, and angiography dyes, which are used in the office setting. We also sell therapeutic products, such as antibiotics, anti-infectives, steroids, steroid combinations, glaucoma medications, decongestants/antihistamines, and anti-edema medications to wholesalers, chain drug stores, and other national account customers. In addition, this segment offers non-pharmaceutical products, including various artificial tear solutions, and preservative-free lubricating ointments. Specialty Therapeutics and Injectable Pharmaceuticals: Liquid and Lyophilized The Company's Specialty Therapeutics and Injectable segment markets hospital drug and injectable pharmaceutical products, including antidotes, anti-infectives, and controlled substances for pain management and anesthesia; and other pharmaceutical products. This segment markets products to hospitals through the wholesale distribution channel. Contract Manufacturing Our Contract Service segment manufactures aseptic filled and terminally sterilized ophthalmic and injectable pharmaceutical products from our facilities in Somerset, NJ and Decatur, IL for third party pharmaceutical customers. Akorn was founded in 1971 and is headquartered in Lake Forest, Illinois.

Alimera Sciences Inc. Medical Support Services | Alpharetta, Georgia

Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.

Competitors
Bausch Health Cos., Inc. Pharmaceuticals - Laval, Canada

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Dr Reddy's Laboratories Ltd. Pharmaceuticals - Hyderabad, India

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API or bulk drugs, which are principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research, development, and manufacture of differentiated formulations and new chemical entities. The Others segment includes the operations of the wholly-owned subsidiary of the company, Aurigene Discovery Technologies Limited, a discovery stage biotechnology company developing novel and best-in-class therapies in the fields of oncology and inflammation and which works with pharmaceutical and biotechnology companies in early-stage collaborations, brining drug candidates for pre-clinical development. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Teva Pharmaceutical Industries Ltd. Pharmaceuticals - Petach Tikva, Isr

Teva is a global generic pharmaceuticals leader and one of the top 15 pharmaceutical companies in the world. Headquartered in Israel, Teva operates in 60 countries and has 46,000 employees worldwide. Established in 1901, Teva takes great pride in its long tradition of leadership and dedication to excellence

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Knight Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Knight Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Knight Therapeutics, Inc..